US Patent 11938224 Benzonatate modified release solid tablets and capsules
Patent 11938224 was granted and assigned to Tris Pharma on March, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 29 Mar, 2024
Golden AI
Edits made to:
Infobox (+40 properties)
Article (+477 characters)
US Patent 11938224 Benzonatate modified release solid tablets and capsules
Article
Patent abstract
A 12-hour anti-tussive modified release solid tablet or tablet-in-capsule is described which comprises a benzonatate-silicon dioxide adsorbate powder in a hydrophilic matrix to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 1% release of the benzonatate within half an hour as determined in an in vitro dissolution assay.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Andrea Nelson0
Nemichand B. Jain0
Sachin Chaudhari0
Shivanand Puthli0
Date of Patent
March 26, 2024
0Patent Application Number
174061370
Date Filed
August 19, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11938224 Benzonatate modified release solid tablets and capsules
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
